Your session is about to expire
← Back to Search
Opioid Antagonist
Intranasal Nalmefene for Pharmacokinetics
Phase 1
Waitlist Available
Led By Robert Bass, MD
Research Sponsored by Opiant Pharmaceuticals Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours
Awards & highlights
Summary
This study is to determine the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given intranasally (IN;into the nose) compared to a dose of nalmefene when given intramuscularly (IM; into the muscle); to compare the blood levels of nalmefene when given IN to nalmefene when given IM; and to evaluate the safety and tolerability of nalmefene IN.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 48 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Area Under the Curve (AUC-inf)
Half-life (t1/2)
Maximum Plasma Concentration (Cmax)
+1 moreSide effects data
From 2021 Phase 1 trial • 68 Patients • NCT0475976856%
nasal discomfort
6%
dizziness
5%
headache
3%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Intranasal Nalmefene
Intramuscular Nalmefene
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intranasal NalmefeneExperimental Treatment1 Intervention
Nalmefene hydrochloride nasal spray, 3mg, 1 spray
Group II: Intramuscular NalmefeneActive Control1 Intervention
Nalmefene injection, 1mg, 1 injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nalmefene
FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Opiant Pharmaceuticals IncLead Sponsor
2 Previous Clinical Trials
108 Total Patients Enrolled
Robert Bass, MDPrincipal InvestigatorWorldwide Clinical Trials
2 Previous Clinical Trials
84 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger